SCHEMBL12290100

SCHEMBL12290100

CNCCCN(CCO)CCO

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT3 O60678 1/20 0.38
CARM1 Q86X55 1/20 0.38
PRMT6 Q96LA8 1/20 0.38
PRMT1 Q99873 1/20 0.38
PRMT8 Q9NR22 1/20 0.38
EPHX1 P07099 1/20 0.36
MAPT P10636 2/20 0.35
MAPK1 P28482 2/20 0.33
MEN1 O00255 1/20 0.33
ALDH1A1 P00352 1/20 0.33
EGFR P00533 1/20 0.33
LMNA P02545 1/20 0.33
POLB P06746 1/20 0.33
HTT P42858 1/20 0.33
RAD52 P43351 1/20 0.33
RECQL P46063 1/20 0.33
BLM P54132 1/20 0.33
KMT2A Q03164 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8306556 1.00 PRMT3 (0.38) PRMT3CARM1PRMT6PRMT1PRMT8
SCHEMBL25075403 0.95 EPHX1 (0.39) PRMT3CARM1PRMT6PRMT1PRMT8
SCHEMBL25075399 0.95 EPHX1 (0.39) PRMT3CARM1PRMT6PRMT1PRMT8
SCHEMBL3076001 0.93 EPHX1 (0.42) PRMT3CARM1PRMT6PRMT1PRMT8
SCHEMBL16256663 0.91 EPHX1 (0.41) PRMT3CARM1PRMT6PRMT1PRMT8
SCHEMBL903463 0.89 EPHX1 (0.39) PRMT3CARM1PRMT6PRMT1PRMT8
SCHEMBL15569827 0.89 PRMT3 (0.45) PRMT3CARM1PRMT6PRMT1PRMT8
SCHEMBL3317331 0.88 CYP1A2 (0.45) PRMT3CARM1PRMT6PRMT1PRMT8
SCHEMBL8305883 0.86 PRMT3 (0.46) PRMT3CARM1PRMT6PRMT1PRMT8
Trolamine SCHEMBL4857518 0.86 PRMT3 (0.39) PRMT3CARM1PRMT6PRMT1PRMT8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022125589-A1 LIPIDOID COMPOSITIONS AND METHODS OF USE THEREOF TRUSTEES OF TUFTS COLLEGE (US) 2022-06-16 WO disclosed
EP-2571973-B1 OPTICAL BRIGHTENERS AND COMPOSITIONS COMPRISING THE SAME MILLIKEN & CO (US) 2020-04-01 EP disclosed
WO-2019150138-A1 CONJUGATES OF CYCLODEXTRINS AND DEFERASIROX OR ANALOGUES THEREOF THE UNIVERSITY OF SUSSEX (GB) 2019-08-08 WO disclosed
US-9150753-B2 Method for making waterborne polyurethane with a reactive functional group and a nanocomposite made of the same NATIONAL CHUNG SHAN INSTITUTE OF SCIENCE AND TECHNOLOGY (TW) 2015-10-06 US disclosed
US-9150753-B2 Method for making waterborne polyurethane with a reactive functional group and a nanocomposite made of the same NATIONAL CHUNG SHAN INSTITUTE OF SCIENCE AND TECHNOLOGY (TW) 2015-10-06 US disclosed
US-9018151-B2 Optical brighteners and compositions comprising the same MILLIKEN & COMPANY (US) 2015-04-28 US disclosed
US-20140343224-A1 Method for Making Waterborne Polyurethane with a Reactive Functional Group and a Nanocomposite Made of the Same NATIONAL CHUNG SHAN INSTITUTE OF SCIENCE AND TECHNOLOGY (TW) 2014-11-20 US disclosed
US-20140343224-A1 Method for Making Waterborne Polyurethane with a Reactive Functional Group and a Nanocomposite Made of the Same NATIONAL CHUNG SHAN INSTITUTE OF SCIENCE AND TECHNOLOGY (TW) 2014-11-20 US disclosed
US-8740997-B2 Optical brighteners and compositions comprising the same MILLIKEN & COMPANY (US) 2014-06-03 US disclosed
US-20130281347-A1 OPTICAL BRIGHTENERS AND COMPOSITIONS COMPRISING THE SAME MILLIKEN & COMPANY 2013-10-24 US disclosed
US-8454711-B2 Optical brighteners and compositions comprising the same MILLIKEN & COMPANY (US) 2013-06-04 US disclosed
WO-2011104334-A1 4 - [CYCLOALKYLOXY (HETERO) ARYLAMINO] THIENO [2, 3 - D] PYRIMIDINES HAVING MNKL/ MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-09-01 WO disclosed
US-7956060-B2 Pyrimidine derivative compound KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-06-07 US disclosed
US-7956060-B2 Pyrimidine derivative compound KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-06-07 US disclosed
US-20100016319-A1 ARYLMETHYLENE UREA DERIVATIVE AND USE THEREOF TORAY INDUSTRIES, INC. A CORPORATION OF JAPAN (JP) 2010-01-21 US disclosed
US-7524852-B2 Bicyclic pyrimidine derivatives KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-04-28 US disclosed
US-7524852-B2 Bicyclic pyrimidine derivatives KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-04-28 US disclosed
US-7183409-B2 Basic mono- and bisazo compounds CLARIANT FINANCE (BVI) LIMITED (VG) 2007-02-27 US disclosed
US-7183409-B2 Basic mono- and bisazo compounds CLARIANT FINANCE (BVI) LIMITED (VG) 2007-02-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016319-A1 ARYLMETHYLENE UREA DERIVATIVE AND USE THEREOF UROD, UTS2R, SLC14A1 PRMT3 378/4885CARM1 520/4885PRMT6 660/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.